Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing
treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) …

Abstract Purpose of Review The extensive genomic characterization of acute myeloid
leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We …

Aberrant changes in the epigenome are now recognized to be important in driving the
development of multiple human cancers including acute myeloid leukemia. Recent …

Abstract Isocitrate dehydrogenase 1 (IDH1) gene aberrations have recently been reported in
acute myeloid leukemia (AML). To evaluate the prognostic significance of IDH1 mutations in …

Recurrent mutations affecting cellular metabolism and epigenetic regulation are implicated
in the pathogenesis of acute myeloid leukemia (AML). Isocitrate dehydrogenase 2 (IDH2) …

In recent years, research in molecular genetics has been instrumental in deciphering the
molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of …

The development of effective treatment strategies for most forms of acute myeloid leukemia
(AML) has languished for the past several decades. There are a number of reasons for this …

Abstract Purpose of Review Awareness of the molecular landscape of AML has improved
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …

Abstract Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent
activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients …